<DOC>
	<DOCNO>NCT00612755</DOCNO>
	<brief_summary>A study concern viral kinetic 10 co-infected HIV-HCV patient treatment peginterferon alfa-2a + ribavirin IFN + ribavirin report Conference Retroviruses Opportunistic Infections 2002 Dr. Torriani show half-life HCV virion viral clearance large mono-infected patient . The doubt difference viral kinetic HIV-HCV co-infected patient versus mono-infected related loss profit treatment . In APRICOT trial patient genotype 2/3 treat 48 week relapse rate 2 % . The present study want evaluate treatment extent 24 week patient genotype 1 and/or 4 improve percentage patient viral clearance end follow-up period , prevent relapse patient response end treatment . Patients randomize receive 180 µg/week peginterferon alfa-2a + 1000-1200 mg/day ribavirin 24 week control .</brief_summary>
	<brief_title>Efficacy Safety Extend Treatment 24 Weeks co-Infected HIV-HCV Genotype 1 and/or 4</brief_title>
	<detailed_description>To evaluate efficacy extend treatment 24 week co-infected HIV-HCV patient genotype 1 and/or 4 44 week treatment peginterferón alfa-2a combination ribavirin RNA-HCV undetectable .</detailed_description>
	<mesh_term>Hepatitis</mesh_term>
	<mesh_term>Hepatitis C</mesh_term>
	<mesh_term>HIV Infections</mesh_term>
	<mesh_term>Ribavirin</mesh_term>
	<mesh_term>Peginterferon alfa-2a</mesh_term>
	<mesh_term>Interferon-alpha</mesh_term>
	<criteria>Patients treatment Peginterferon alfa2a ( 180 µg/week ) combination Ribavirin ( 10001200 mg/day ) RNAHCV undetectable 44 week RNAHCV positive 48 week study genotype 1 4 . HIV1 positive : ELISA Westernblot . Stable status HIV1 infection opinion investigator , ( patient expect progress study ) . Negative urine blood pregnancy test ( woman childbearing potential ) document within 24hour period prior first dose study drug . Additionally , fertile male female must use two form effective contraception treatment 6 month treatment end . This may include , limited , use birth control pill , IUDs , condom , diaphragm , implant , surgically sterilize , postmenopausal state . Willingness give write informed consent willingness participate comply study . Patients RNAHCV detectable 44 week treatment Peginterferon alfa2a ( 180 µg/week ) combination Ribavirin ( 10001200 mg/day ) . Patients treatment chronic hepatitis , different inclusion criterion describe . More tree week end treatment Peginterferon alfa2a ( 180 µg/week ) combination Ribavirin ( 10001200 mg/day ) inclusion `` EXTRADOS '' trial .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>65 Years</maximum_age>
	<verification_date>January 2008</verification_date>
	<keyword>chronic hepatitis C</keyword>
	<keyword>co-infection</keyword>
	<keyword>extend treatment</keyword>
	<keyword>co-infected HIV-HCV</keyword>
</DOC>